Next generation
small molecules

Targeting high value disease drivers for major unmet needs in Oncology

About

Founded in 2017, Nalo’s mission is to address unmet needs in cancer by developing therapeutics targeting oncogenic driver mutations and/or proteins that are well-known but often hard to drug.

In collaboration with our UCSF scientific cofounders, Nalo set out to tackle one of the most challenging and well know drug targets in oncology: the Myc oncoprotein. Utilizing new insights into the biology of the Myc protein and its’ regulation by the cell, Nalo has developed small molecules that induce the natural degradation of the Myc protein that leads to cancer cell apoptosis.  

To expand our pipeline, in 2021, Nalo acquired a clinical-ready small molecule asset, a next generation brain-penetrant EGFR inhibitor, NX-019, to address significant unmet needs in EGFR mutant Non-Small Cell Lung Cancer (NSCLC).  NX-019 is designed to selectively spare wild-type EGFR and efficiently cross the blood brain barrier (BBB).  NX-019 is now in a FIH clinical study in NSCLC in the US and Asia.

LEADerSHIP Team

Keith Wilson, PhD

Founder, President & CSO

Stephen Shuttleworth, PhD

CTO

Rachel Dusek, PhD

VP Translational Medicine

Cory Freedland, PhD

Board Member

David Parry, PhD

Board Member

Srini Akkaraju, MD, PhD

Founder

Science

NX‑019 – a next generation brain penetrant, wild-type sparing EGFR inhibitor with broad mutant EGFR activities

Nalo has taken NX-019 into clinical trials to address a several unmet needs in Non-small cell lung cancer (NSCLC) and other cancers. NX-019 is a small molecule targeting mutant forms of the Epidermal Growth Factor Receptor (EGFR) which drive tumor formation. NX-019 targets nearly all mutant forms of EGFR and was rationally designed to cross the brain blood barrier to address the high unmet need of brain metastases in mutant EGFR NSCLC.

NX‑201 – a novel small molecule approach to targeted Myc degradation

Nalo has tackled one of the best-known disease drivers in cancer: the Myc transcription factor. Leveraging insights and expertise from our scientific founders at the University of California, San Francisco, we have rationally designed molecules that target the Myc protein, shutting off the cellular programming that leads to cancer progression. Clinical trials for these molecules are in preparation.

Clinical Development

Nalo sponsored clinical trial NT‑019‑101

A Study of NX-019 in Patients With Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer.

To learn more about this clinical study please visit clinicaltrials.gov, study identifier NCT05514496

Careers

Journey with us

Nalo Therapeutics is a highly integrated and diverse team of experienced individuals with comprehensive skills in basic research, medicinal chemistry, pre-clinical and clinical development. We are committed to continuing to build a dynamic and collaborative team of exceptional and dedicated professionals working with a passion to make quick impacts and deliver truly effective medicines to cancer patients with high unmet needs.

Open positions

We currently do not have any open positions.  If you are interested in learning more about Nalo Therapeutics and potential future positions, please contact us at info@nalotherapeutics.com.

Corporate News